Filing Flows › Collegium Pharmaceutical (COLL) › Capital expenditures
Collegium Pharmaceutical (COLL) capital expenditures by quarter
Collegium Pharmaceutical's capital expenditures were $277K in Q3 2026 (third quarter 2026), -44% from Q2 2026. Over the last 7 quarters it ranged from $65K (Q2 2025) to $798K (Q1 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $277K | -44% | +47% |
| Q2 2026 | $496K | +84% | +663% |
| Q1 2026 | $270K | -61% | -66% |
| Q4 2025 | $689K | +266% | — |
| Q3 2025 | $188K | +189% | — |
| Q2 2025 | $65K | -92% | — |
| Q1 2025 | $798K | — | — |
Q3 2026 at a glance
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Collegium Pharmaceutical's capital expenditures?
Collegium Pharmaceutical's capital expenditures were $277K in Q3 2026 (third quarter 2026), -44% from Q2 2026.
How has Collegium Pharmaceutical's capital expenditures changed?
Over the last 7 quarters it ranged from $65K (Q2 2025) to $798K (Q1 2025).
Q3 2026 results → · How Collegium Pharmaceutical makes money →